newsfilter
← Latest News
GlobeNewswire·

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- 60